Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 14, 2017; 23(2): 366-372
Published online Jan 14, 2017. doi: 10.3748/wjg.v23.i2.366
Published online Jan 14, 2017. doi: 10.3748/wjg.v23.i2.366
Medications | Non-FDA approved weight loss supplements, sertraline, temozolomide, oxcarbazepine, levofloxacin,ibuprofen, sulfamethoxaxzole-trimethoprim, meropenom, lamotrigine , valproic acid, azithromycin, moxifloxacin, chlorpromazine, carbamazepine, interferon, mycophenolate mofetil, anabolic steroids, allopurinol |
Infections | Human immunodeficiency virus (HIV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), cryptosporidium, reovirus type 3 |
Malignancy | Lymphoma (B-cell, T-cell rich B-cell, Hodgkin’s, non-Hodgkin’s, and anaplastic large cell) |
Immunologic | Primary biliary cholangitis, primary sclerosing cholangitis, sarcoidosis, chronic graft vs host disease |
- Citation: Bakhit M, McCarty TR, Park S, Njei B, Cho M, Karagozian R, Liapakis A. Vanishing bile duct syndrome in Hodgkin’s lymphoma: A case report and literature review. World J Gastroenterol 2017; 23(2): 366-372
- URL: https://www.wjgnet.com/1007-9327/full/v23/i2/366.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i2.366